117 related articles for article (PubMed ID: 34449480)
21. Factors related to patient propensity to receive adjuvant chemotherapy and outcomes in stage III gastric cancer cases after D2 surgery.
Chen JS; Hung CY; Liu KH; Tsai CY; Kuo YC; Hsu JT; Chou WC
Asian J Surg; 2019 May; 42(5):604-612. PubMed ID: 30249414
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis.
Stumpf PK; Amini A; Jones BL; Koshy M; Sher DJ; Lieu CH; Schefter TE; Goodman KA; Rusthoven CG
Cancer; 2017 Sep; 123(17):3402-3409. PubMed ID: 28513823
[TBL] [Abstract][Full Text] [Related]
23. 15-PGDH expression as a predictive factor response to neoadjuvant chemotherapy in advanced gastric cancer.
Hu M; Li K; Maskey N; Xu Z; Peng C; Tian S; Li Y; Yang G
Int J Clin Exp Pathol; 2015; 8(6):6910-8. PubMed ID: 26261578
[TBL] [Abstract][Full Text] [Related]
24. Clinical Features and Survival of Young Adults with Stage IV Gastric Cancer: a Japanese Population-Based Study.
Yamamoto R; Honda M; Kawamura H; Kobayashi H; Takiguchi K; Muto A; Yamazaki S; Teranishi Y; Shiraso S; Kono K; Hori S; Kamiga T; Iwao T; Yamashita N
J Gastrointest Cancer; 2023 Mar; 54(1):56-61. PubMed ID: 34994916
[TBL] [Abstract][Full Text] [Related]
25. Prealbumin-to-Globulin Ratio Can Predict the Chemotherapy Outcomes and Prognosis of Patients with Gastric Cancer Receiving First-Line Chemotherapy.
Wang Z; Zhang L; Wang J; Wang Y; Dong Q; Piao H; Wang Q; Zhang J
J Immunol Res; 2020; 2020():6813176. PubMed ID: 32832571
[TBL] [Abstract][Full Text] [Related]
26. The addition of chemoradiation to adjuvant chemotherapy is associated with improved survival in lymph node-positive gastric cancer.
Altman AM; Sheka AC; Marmor S; Lou E; Reynolds M; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
Surg Oncol; 2020 Sep; 34():134-139. PubMed ID: 32891318
[TBL] [Abstract][Full Text] [Related]
27. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Ito S; Ohashi Y; Sasako M
BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
[TBL] [Abstract][Full Text] [Related]
28. Immunoscore is a strong predictor of survival in the prognosis of stage II/III gastric cancer patients following 5-FU-based adjuvant chemotherapy.
Yun S; Koh J; Nam SK; Kwak Y; Ahn SH; Do Park J; Kim HH; Kim WH; Lee HS
Cancer Immunol Immunother; 2021 Feb; 70(2):431-441. PubMed ID: 32785776
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer.
Wang Y; Wang C; Xiao H; Niu C; Wu H; Jin H; Yao C; He H; Tian H; Han F; Li D; Han W; Xu J; Chen J; Cui J; Li W
Cancer Med; 2017 Jan; 6(1):45-53. PubMed ID: 27790867
[TBL] [Abstract][Full Text] [Related]
30. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.
Fujitani K; Yang HK; Mizusawa J; Kim YW; Terashima M; Han SU; Iwasaki Y; Hyung WJ; Takagane A; Park DJ; Yoshikawa T; Hahn S; Nakamura K; Park CH; Kurokawa Y; Bang YJ; Park BJ; Sasako M; Tsujinaka T;
Lancet Oncol; 2016 Mar; 17(3):309-318. PubMed ID: 26822397
[TBL] [Abstract][Full Text] [Related]
31. Comparison of efficacy in adjuvant chemotherapy regimens in patients with radically resected gastric cancer : a propensity-matched analysis.
Quan R; Huang J; Chen H; Liao Y; Lv W; Chen N; Liu J; Zhang H; Xu D
Oncotarget; 2016 Nov; 7(46):76316-76326. PubMed ID: 27602756
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of docetaxel- and oxaliplatin-based adjuvant chemotherapy in postgastrectomy gastric cancer patients reveals obvious survival benefits in docetaxel-treated mixed signet ring cell carcinoma patients.
Chen L; Shi Y; Yuan J; Wu Q; Han Y; Qin R; Jia B; Wei B; Wei L; Dai G; Jiao S
Med Oncol; 2014 Sep; 31(9):159. PubMed ID: 25119501
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Di Costanzo F; Gasperoni S; Manzione L; Bisagni G; Labianca R; Bravi S; Cortesi E; Carlini P; Bracci R; Tomao S; Messerini L; Arcangeli A; Torri V; Bilancia D; Floriani I; Tonato M; ; Dinota A; Strafiuso G; Corgna E; Porrozzi S; Boni C; Rondini E; Giunta A; Monzio Compagnoni B; Biagioni F; Cesari M; Fornarini G; Nelli F; Carboni M; Cognetti F; Enzo MR; Piga A; Romiti A; Olivetti A; Masoni L; De Stefanis M; Dalla Mola A; Camera S; Recchia F; De Filippis S; Scipioni L; Zironi S; Luppi G; Italia M; Banducci S; Pisani Leretti A; Massidda B; Ionta MT; Nicolosi A; Canaletti R; Biscottini B; Grigniani F; Di Costanzo F; Rovei R; Croce E; Carroccio R; Gilli G; Cavalli C; Olgiati A; Pandolfi U; Rossetti R; Natalini G; Foa P; Oldani S; Bruno L; Cascinu S; Catalano G; Catalano V; Lungarotti F; Farris A; Sarobba MG; Trignano M; Muscogiuri A; Francavilla F; Figoli F; Leoni M; Papiani G; Orselli G; Antimi M; Bellini V; Cabassi A; Contu A; Pazzola A; Frignano M; Lastraioli E; Saggese M; Bianchini D; Antonuzzo L; Mela M; Camisa R
J Natl Cancer Inst; 2008 Mar; 100(6):388-98. PubMed ID: 18334706
[TBL] [Abstract][Full Text] [Related]
34. Pre-adjuvant chemotherapy leukocyte count may predict the outcome for advanced gastric cancer after radical resection.
Pei D; Zhu F; Chen X; Qian J; He S; Qian Y; Shen H; Liu Y; Xu J; Shu Y
Biomed Pharmacother; 2014 Mar; 68(2):213-7. PubMed ID: 24581723
[TBL] [Abstract][Full Text] [Related]
35. Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer.
Sylvie L; Silvia S; Salah-Eddin AB; Markus F; Florian L; Peter TP; Bernhard H; Martin A; Alexander N
Eur J Cancer; 2015 Sep; 51(14):1918-26. PubMed ID: 26216588
[TBL] [Abstract][Full Text] [Related]
36. Association of Antioxidative Enzymes Polymorphisms with Efficacy of Platin and Fluorouracil-Based Adjuvant Therapy in Gastric Cancer.
Zhang H; Zhao W; Gu D; Du M; Gong W; Tan Y; Wang M; Wen J; Zhai Y; Xu Z
Cell Physiol Biochem; 2018; 48(6):2247-2257. PubMed ID: 30114685
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant Radiation Therapy Treatment Time Impacts Overall Survival in Gastric Cancer.
McMillan MT; Ojerholm E; Roses RE; Plastaras JP; Metz JM; Mamtani R; Karakousis GC; Fraker DL; Drebin JA; Stripp D; Ben-Josef E; Datta J
Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):326-36. PubMed ID: 26232857
[TBL] [Abstract][Full Text] [Related]
38. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.
Su Y; Lin L; Zhang J; Jiang Y; Pan C; Sun L; Duan J; Liao W
Mol Med Rep; 2015 Oct; 12(4):5771-9. PubMed ID: 26239822
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer.
Wu Y; Wei ZW; He YL; Schwarz RE; Smith DD; Xia GK; Zhang CH
World J Gastroenterol; 2013 Jun; 19(21):3309-15. PubMed ID: 23745033
[TBL] [Abstract][Full Text] [Related]
40. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Bang YJ; Xu RH; Chin K; Lee KW; Park SH; Rha SY; Shen L; Qin S; Xu N; Im SA; Locker G; Rowe P; Shi X; Hodgson D; Liu YZ; Boku N
Lancet Oncol; 2017 Dec; 18(12):1637-1651. PubMed ID: 29103871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
